Cti Biopharma reported $30.42M in Cash and Equivalent for its fourth fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Cash And Equivalent Change
Baxter International BAX:US USD 1.72B 117M
Bristol Myers Squibb BMY:US USD 9.12B 1.39B
Cti Biopharma CTIC:US USD 30.42M 1.63M
Cytori Therapeutics CYTX:US USD 18.12M 2.15M
Geron GERN:US USD 56.84M 4.26M
Mirati Therapeutics MRTX:US USD 182.23M 8.69M
Northwest Biotherapeutics NWBO:US USD 9.42M 4.59M
Novartis NOVN:VX USD 7.52B 1.21B
Novartis NVS:US USD 7.52B 1.21B
Seattle Genetics SGEN:US USD 319.94M 42.66M
Teva Pharmaceutical Industries TEVA:US USD 2.8B 576M
YTE INCY:US USD 2.95B 260.8M